Scientists Discover a Plant Compound That Could Help Stop Rheumatoid Arthritis Inflammation

Scientists studying a compound found in medicinal plant bark have uncovered a possible new way to treat rheumatoid arthritis. In a 21-day experiment, researchers found that obakulactone reduced joint swelling and inflammatory activity in rats with experimentally induced arthritis.

The research goes beyond the familiar story of a plant substance showing promise in the laboratory. Scientists identified a protein involved in fatty acid metabolism that appears to contribute to the compound's effects, offering a more specific direction for future research. The findings show how obakulactone influenced arthritis inflammation in animals, though its effectiveness in people remains to be established.

Scientists Observed Reduced Swelling and Joint Damage Obakulactone improved several signs of inflammatory arthritis during controlled experiments involving laboratory rats. The compound comes from Phellodendri cortex, the bark of a medicinal plant that researchers examined for its potential anti-inflammatory effects.

Their investigation used rats with arthritis induced by complete Freund's adjuvant, a substance used to create an experimental model of inflammatory arthritis. The animals received obakulactone daily for 21 days at doses of 50, 100, or 200 milligrams per kilogram of body weight. This approach allowed the researchers to examine how different doses of the compound affected the animals.

Following treatment, researchers observed reduced joint swelling and improvements in cartilage and synovial tissue, which lines the joints. They also documented improvements in arthritis-related changes in the thymus and spleen, two organs involved in immune function. Blood and laboratory analyses further supported the compound's effects.

Researchers reported reductions in inflammatory signaling molecules, including IL-1β, IL-6, IL-17, and TNF-α, which participate in inflammatory responses. They also observed changes in rheumatoid factor, antibodies against cyclic citrullinated peptides, and C-reactive protein, markers relevant to their assessment of inflammatory activity.

The experiments additionally revealed changes involving macrophages and T helper 17 cells, both of which participate in immune responses. Some effects became more pronounced at higher administered doses, suggesting that certain responses increased with the amount of compound given.

Related: 7 Critical Old Age Symptoms You Must Never Overlook A Protein Called ACOT1 Could Be Central to the Discovery The most significant finding may be how obakulactone interacts with a protein involved in fatty acid metabolism. Researchers identified ACOT1, or acyl-CoA thioesterase 1, as the compound's molecular target.

Understanding that interaction could help explain why the treated animals showed improvements in several measures of inflammatory arthritis. Laboratory experiments showed that obakulactone binds to ACOT1 and promotes its degradation through the ubiquitin-proteasome system, a cellular process that breaks down proteins.

This interaction was linked to changes in unsaturated fatty acid metabolism and reduced activity in two signaling pathways: JAK-STAT and PI3K-AKT. Both pathways influence inflammatory responses. These findings may explain the improvements observed in the animals.

In their published study, the researchers described obakulactone as "a potential RA therapeutic agent." Identifying ACOT1 also gives scientists a specific molecular target to investigate. Rather than focusing solely on the compound's ability to reduce visible swelling, future research can examine whether influencing this protein offers a useful approach to controlling inflammatory activity.

The Discovery First Appeared Months Before October's Coverage Image Credit: sebra/123RF The renewed attention follows research that entered the scientific literature earlier in 2026. The study was published on January 29, 2026, in Engineering, Volume 56, pages 341 through 360. Its findings were therefore already publicly available months before the October coverage brought the compound back into focus.

On April 24, Higher Education Press issued a research announcement through EurekAlert, describing the animal experiments and the proposed ACOT1 mechanism. The findings received additional coverage in April, followed by a ScienceDaily report in July . These reports concern the same underlying scientific investigation, rather than successive clinical breakthroughs.

The publication history helps establish where the discovery currently stands: researchers have documented experimental findings and proposed a biological mechanism, but the available study does not report a human clinical trial. Why the Plant Compound Is Different From an Herbal Remedy The researchers tested an isolated chemical compound, not the plant bark as a treatment for people with arthritis.

Obakulactone's natural origin is central to the discovery, but the distinction between a plant and a compound obtained from it matters. The experiment examined how a specific substance behaved when administered in measured quantities under controlled laboratory conditions. The scientists did not test whether consuming Phellodendri cortex bark, drinking herbal preparations, or taking supplements would produce comparable results.

Their findings therefore cannot establish that bark-derived products produce the same effects. The animal experiments also could not answer other questions. The study did not determine an effective human dosage, establish long-term safety in patients, or demonstrate that obakulactone performs better than existing rheumatoid arthritis medications.

Nor did it establish when, or whether, a treatment based on the compound might become available. Those uncertainties do not erase the laboratory findings. Still, they define the next scientific challenge: determining whether the biological effects observed in experimental arthritis translate into a safe, meaningful benefit for people.

For now, obakulactone offers researchers something concrete to pursue, a compound with documented experimental effects and a molecular target that may help explain them. The discovery adds another possibility to rheumatoid arthritis research, while leaving the most consequential questions for future investigation.

What will researchers need to establish before this promising laboratory discovery can become a treatment option for people living with rheumatoid arthritis? More Articles You Might Like: The post Scientists Discover a Plant Compound That Could Help Stop Rheumatoid Arthritis Inflammation appeared first on FODMAP Everyday .